Characterization of hematopoietic organs in gp130Y757F/Y757F mice
Parameter . | +/+, mean ± SD* . | F/F, mean ± SD* . |
|---|---|---|
| Bone marrow | ||
| Cellularity per femur, × 107 | 3.58 ± 0.26 | 3.50 ± 1.02 |
| Blasts, % | 3 + 1 | 4 + 2 |
| Promyelocytes/myelocytes, % | 7 ± 2 | 10 ± 2 |
| Metamyelocytes/neutrophils, % | 27 ± 4 | 46 ± 7§ |
| Lymphocytes, % | 32 ± 7 | 21 ± 8 |
| Monocytes, % | 5 ± 1 | 4 ± 1 |
| Eosinophils, % | 3 ± 2 | 2 ± 1 |
| Nucleated RBCs, % | 23 ± 6 | 14 ± 3 |
| Megakaryocytes, per 10 hpf† | 88 ± 10 | 132 ± 17§ |
| Spleen | ||
| Mass, mg | 79 ± 16 | 203 ± 63§ |
| Cellularity, × 108 | 1.70 ± 0.71 | 3.63 ± 1.22§ |
| Blasts, % | 0 ± 0 | 0 ± 0 |
| Promyelocytes/myelocytes, % | 0 ± 0 | 0 ± 0 |
| Metamyelocytes/neutrophils, % | 2 ± 1 | 6 ± 1§ |
| Lymphocytes, % | 89 ± 6 | 76 ± 7 |
| Monocytes, % | 2 ± 1 | 2 ± 1 |
| Eosinophils, % | 0 ± 0 | 0 ± 0 |
| Nucleated RBCs, % | 7 ± 5 | 16 ± 6§ |
| Megakaryocytes, per 10 hpf† | 11 ± 5 | 76 ± 2§ |
| Thymus | ||
| Mass, mg | 46 ± 9 | 74 ± 17§ |
| Cellularity, × 108 | 2.01 ± 0.48 | 2.69 ± 0.84 |
| CD4+ CD8+‡§ | 84.63 ± 2.53 | 77.52 ± 5.6§ |
| B220+‡§ | 2.34 ± 1.82 | 4.02 ± 3.1 |
| Lymph nodes | ||
| Mass, mg | 43 ± 10 | 69 ± 13§ |
| Cellularity, × 107 | 2.09 ± 0.45 | 4.59 ± 0.60§ |
| Thy 1.2+‡§ | 57.90 ± 7.39 | 42.88 ± 7.46§ |
| B220+‡ | 39.60 ± 8.38 | 54.5 ± 10.45§ |
Parameter . | +/+, mean ± SD* . | F/F, mean ± SD* . |
|---|---|---|
| Bone marrow | ||
| Cellularity per femur, × 107 | 3.58 ± 0.26 | 3.50 ± 1.02 |
| Blasts, % | 3 + 1 | 4 + 2 |
| Promyelocytes/myelocytes, % | 7 ± 2 | 10 ± 2 |
| Metamyelocytes/neutrophils, % | 27 ± 4 | 46 ± 7§ |
| Lymphocytes, % | 32 ± 7 | 21 ± 8 |
| Monocytes, % | 5 ± 1 | 4 ± 1 |
| Eosinophils, % | 3 ± 2 | 2 ± 1 |
| Nucleated RBCs, % | 23 ± 6 | 14 ± 3 |
| Megakaryocytes, per 10 hpf† | 88 ± 10 | 132 ± 17§ |
| Spleen | ||
| Mass, mg | 79 ± 16 | 203 ± 63§ |
| Cellularity, × 108 | 1.70 ± 0.71 | 3.63 ± 1.22§ |
| Blasts, % | 0 ± 0 | 0 ± 0 |
| Promyelocytes/myelocytes, % | 0 ± 0 | 0 ± 0 |
| Metamyelocytes/neutrophils, % | 2 ± 1 | 6 ± 1§ |
| Lymphocytes, % | 89 ± 6 | 76 ± 7 |
| Monocytes, % | 2 ± 1 | 2 ± 1 |
| Eosinophils, % | 0 ± 0 | 0 ± 0 |
| Nucleated RBCs, % | 7 ± 5 | 16 ± 6§ |
| Megakaryocytes, per 10 hpf† | 11 ± 5 | 76 ± 2§ |
| Thymus | ||
| Mass, mg | 46 ± 9 | 74 ± 17§ |
| Cellularity, × 108 | 2.01 ± 0.48 | 2.69 ± 0.84 |
| CD4+ CD8+‡§ | 84.63 ± 2.53 | 77.52 ± 5.6§ |
| B220+‡§ | 2.34 ± 1.82 | 4.02 ± 3.1 |
| Lymph nodes | ||
| Mass, mg | 43 ± 10 | 69 ± 13§ |
| Cellularity, × 107 | 2.09 ± 0.45 | 4.59 ± 0.60§ |
| Thy 1.2+‡§ | 57.90 ± 7.39 | 42.88 ± 7.46§ |
| B220+‡ | 39.60 ± 8.38 | 54.5 ± 10.45§ |
Values represent the mean ± SD from 5 mice of each genotype
Number of megakaryocytes counted at × 400 magnification (bone marrow) or × 200 magnification (spleen), with 30 high-power fields (hpf) counted per mouse
Percentage of CD4+/CD8+ cells, and B220 or Thy1.2 single-positive cells as determined by flow cytometric analysis of single cell suspensions of thymus and lymph nodes
P < .05 versus data from wild-type (gp 130+/+) mice. No other statistically significant differences were observed between genotypes